AU2001259817A1 - Methods of and compounds for inhibiting calpains - Google Patents
Methods of and compounds for inhibiting calpainsInfo
- Publication number
- AU2001259817A1 AU2001259817A1 AU2001259817A AU5981701A AU2001259817A1 AU 2001259817 A1 AU2001259817 A1 AU 2001259817A1 AU 2001259817 A AU2001259817 A AU 2001259817A AU 5981701 A AU5981701 A AU 5981701A AU 2001259817 A1 AU2001259817 A1 AU 2001259817A1
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- methods
- calpains
- inhibiting
- inhibiting calpains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20237800P | 2000-05-04 | 2000-05-04 | |
| US60/202,378 | 2000-05-04 | ||
| PCT/US2001/040652 WO2001082919A2 (en) | 2000-05-04 | 2001-05-02 | Methods of and compounds for inhibiting calpains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001259817A1 true AU2001259817A1 (en) | 2001-11-12 |
Family
ID=22749625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001259817A Abandoned AU2001259817A1 (en) | 2000-05-04 | 2001-05-02 | Methods of and compounds for inhibiting calpains |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6448245B1 (en) |
| AU (1) | AU2001259817A1 (en) |
| WO (1) | WO2001082919A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003030886A2 (en) * | 2001-10-05 | 2003-04-17 | Elan Pharmaceuticals, Inc | Allylamides useful in the treatment of alzheimer's disease |
| CA2465316A1 (en) * | 2001-10-29 | 2003-05-08 | James P. Beck | Hydroxy substituted amides for the treatment of alzheimer's disease |
| US20030138423A1 (en) * | 2001-12-14 | 2003-07-24 | Cedars-Sinai Medical Center | Method of treating inflammation with HIV-1 protease inhibitors and their derivatives |
| WO2004052364A1 (en) * | 2002-12-06 | 2004-06-24 | The Trustees Of Boston University | METHODS FOR SUSTAINING eNOS ACTIVITY |
| AU2007275860C1 (en) | 2006-07-07 | 2014-06-12 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| ES2602784T3 (en) * | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Modulators of the pharmacokinetic properties of therapeutic agents |
| CN101796040A (en) * | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | Modulators of the Pharmacokinetic Properties of Therapeutic Agents |
| JP5629585B2 (en) * | 2008-01-04 | 2014-11-19 | ギリアード サイエンシーズ, インコーポレイテッド | Inhibitor of cytochrome P450 |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
| EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
| EP3942931A1 (en) | 2014-06-10 | 2022-01-26 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
| CN104069117A (en) * | 2014-07-03 | 2014-10-01 | 滨州医学院 | Application of amprenavir in preparation of medicine for preventing or treating ischemic cardiovascular and cerebrovascular diseases |
| KR20250047404A (en) | 2015-12-08 | 2025-04-03 | 바이오매트리카 인코포레이티드 | Reduction of erythrocyte sedimentation rate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| DE4215874A1 (en) | 1992-05-14 | 1993-11-18 | Bayer Ag | Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostear type |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| DE19500120A1 (en) | 1995-01-04 | 1996-07-11 | Bayer Ag | New acylated pseudopeptides with trifluoromethyl-substituted 2-azabicyclooctane |
| WO1998020888A1 (en) | 1996-11-08 | 1998-05-22 | Japan Energy Corporation | Aids remedy |
| ZA9710071B (en) | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| GB9712253D0 (en) | 1997-06-13 | 1997-08-13 | Glaxo Group Ltd | Antiviral compound |
-
2001
- 2001-05-02 US US09/847,872 patent/US6448245B1/en not_active Expired - Fee Related
- 2001-05-02 WO PCT/US2001/040652 patent/WO2001082919A2/en not_active Ceased
- 2001-05-02 AU AU2001259817A patent/AU2001259817A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6448245B1 (en) | 2002-09-10 |
| US20020115665A1 (en) | 2002-08-22 |
| WO2001082919A2 (en) | 2001-11-08 |
| WO2001082919A3 (en) | 2002-05-10 |
| WO2001082919B1 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001280599A1 (en) | Compounds and methods | |
| AU2001251358A1 (en) | Prion-binding ligands and methods of using same | |
| AU2001253418A1 (en) | Compounds and methods | |
| AU2001239052A1 (en) | Compositions for prevention and treatment of dementia | |
| AU2001234088A1 (en) | TNF-alpha inhibitors | |
| AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
| AU2002225894A1 (en) | Methods and compositions for the control of coccidiosis | |
| AU2001259817A1 (en) | Methods of and compounds for inhibiting calpains | |
| AU1488501A (en) | Methods of inhibiting metastasis | |
| AU2001286983A1 (en) | Method of treatment | |
| AU2001243394A1 (en) | Compounds and methods | |
| AU2001241468A1 (en) | Method of and system for counterfeit prevention | |
| AU2002220036A1 (en) | Method and system for improving stability of photomasks | |
| AU2001294258A1 (en) | Method of purifying plavastatin | |
| AUPQ872300A0 (en) | Compounds and methods | |
| AU2001261676A1 (en) | Method and reagent for the inhibition of erg | |
| AU5261701A (en) | Method for purification of tetrafluoromethane and use thereof | |
| AU2002214189A1 (en) | Methods of identifying inhibitory compounds and uses thereof | |
| AU2001232245A1 (en) | Tnf- alpha inhibitors | |
| AU2001252884A1 (en) | Method of dopamine inhibition using l-threo-methylphenidate | |
| AU2001264522A1 (en) | Methods and compositions for the prevention of myopia | |
| AU2001278951A1 (en) | Compounds and methods | |
| AUPQ904100A0 (en) | Method of encryption | |
| AU2002303552A1 (en) | Methods and compositions for prevention of angioproliferation | |
| AU2002235277A1 (en) | Compounds and methods |